| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Exact Sciences Corporation
$104.91
-0.02 (-0.02%)
Last traded Mar 20, 2026. This price is not current.
C 42Pipeline Score Diagnostics · Commercial
Market Cap
20.03 B
EPS
-1.10
P/E Ratio
-
Value Trade
2.26 B
1.33 %
Week
1.55 %
1 Month
3.36 %
3 Month
96.53 %
6 Month
-18.67 %
5 Year
611.25 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
21.56 M
52 Week Range
38.81 - 104.98
% held by Insiders
1.59 %
% held by Institutions
86.16 %
Enterprise Value
21.60 B
Total Shares
189.38 M
Short %
4.18 %
Float Shares
187.67 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C42
Pipeline Score $1.2B
Pipeline ValueValuation Signal
2
Drugs Scored0.1x
rNPV / MCap Top 66%
Mid Cap (rank 318 of 933)
Percentile RankExact Sciences Corporation carries a moderate pipeline score (42/100), with $1.4B risk-adjusted pipeline value, led by Ribociclib in Breast Cancer Female (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ribociclib Small molecule | Breast Cancer Female | Phase 3 | NCT04055493 | 46% | $980M | ACTIVE NOT_RECRUITING | 1,684 | - | - | Jul 31, 2027 | - | Aug 26, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Oncodetect® | early triple-negative breast cancer | — | 2026-03-17 | Pre-surgery ctDNA status following neoadjuvant therapy (NAT) was strongly associated with both pathologic complete response (pCR) and distant recurrence-free interval (dRFI). Read More | Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026 Read More | |
Oncodetect® | early triple-negative breast cancer | — | 2026-03-17 | Pre-surgery ctDNA status following neoadjuvant therapy (NAT) was strongly associated with both pathologic complete response (pCR) and distant recurrence-free interval (dRFI). Read More | Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026 Read More | |
Oncodetect® | early triple-negative breast cancer | — | 2026-03-17 | Pre-surgery ctDNA status following neoadjuvant therapy (NAT) was strongly associated with both pathologic complete response (pCR) and distant recurrence-free interval (dRFI). Read More | Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EXAS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EXAS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How EXAS ranks across every disease it competes inCompetitive Position is a premium feature
See how EXAS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial